Compositions and methods for ophthalmic and/or other applications

A pharmaceutical composition comprising:

• (a) a plurality of particles of loteprednol etabonate;
• (b) about 0.5% w/v to about 3% w/v glycerin;
• (c) an ionic tonicity agent;
• and
• (d) poloxamer 407;
• wherein the particles of loteprednol etabonate are non-covalently coated with the poloxamer 407 to form coated nanoparticles, and wherein the coated nanoparticles are mucus-penetrating;
• wherein the pharmaceutical composition comprises loteprednol etabonate at about 1% w/v in total;
• and
• wherein the pharmaceutical composition is a topical suspension, and wherein the ratio of the total weight of the loteprednol etabonate to the total weight of the poloxamer 407 comprised in the topical suspension is about 2:1.

A pharmaceutical composition, comprising:

• (a) a plurality of coated nanoparticles, each of the coated nanoparticles comprising:
• (i) a core particle comprising a single pharmaceutical agent, wherein the single pharmaceutical agent is loteprednol etabonate, and wherein the loteprednol etabonate comprises at least 90 wt % of the core particle;
• and
• (ii) a coating on the core particle, the coating comprising poloxamer 407 non-covalently adsorbed to the core particle;
• and
• (b) one or more ophthalmically acceptable carriers, additives, and/or diluents;
• wherein the pharmaceutical composition is a topical suspension, and wherein the topical suspension comprises about 1% w/v loteprednol etabonate in total and about 0.5% w/v poloxamer 407 in total, and
• wherein the coated nanoparticles are mucus-penetrating.